Revised Korean Innovative Drug Pricing System Draws Strong Pharma Objections
Executive Summary
Local and multinational pharma associations voice objections to proposed revisions to innovative drug pricing system in South Korea as part of a revised US trade deal, respectively demanding a complete change to the revised rules and dubbing it "unrealistic", with almost no new drugs expected to qualify for preferential pricing.